AVECHO BIOTECHNOLOGY LIMITED — Board/Management Information 2021

May 3, 2021

==> picture [77 x 35] intentionally omitted <==

==> picture [24 x 26] intentionally omitted <==

==> picture [22 x 35] intentionally omitted <==

==> picture [26 x 26] intentionally omitted <==

ASX Announcement

4 May 2021

ASX Market Announcements ASX Limited Level 4, North Tower, Rialto 525 Collins Street Melbourne VIC 3000

RESIGNATION OF DIRECTOR WITHDRAWAL OF AGM RESOLUTIONS

Melbourne , Australia, 4 May 2021 - Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”), a company that develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM[®] , advises that Mr David Segal has resigned as a director of the Company and will effectively retire from office at the conclusion of the Annual General Meeting of 31 May 2021.

Mr Segal was the Investor Relations Manager of the Company from 2011 to 2015 prior to his appointment as Director of the Company in May 2016. He has been a valuable asset to the Company and has contributed to the Company’s growth. The remaining directors wish to thank Mr David Segal all the best in his future endeavours. Mr David Segal’s Appendix 3Z will be lodged on or about 31 May 2021.

Resolutions 2 and 4 in the Notice of Annual General Meeting, as lodged on 30 April 2021, which respectively pertain to the re-election of Mr Segal as Director of the Company and the approval to grant Options to Mr David Segal, are withdrawn from the business of the meeting.

For enquiries, please contact

Ms Melanie Leydin Avecho Biotechnology Limited +61 3 9002 5000

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

About Avecho

Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM® (Tocopherol Phosphate Mixture). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho’s major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM® to cannabinoids. The Company is also developing TPM[®] to enhance feed efficiency and health of livestock.

See more here - avecho.com.au

Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403 Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168

avecho.com.au